{
    "eid": "2-s2.0-85098986039",
    "title": "Effects of Angiotensin II Receptor Blockers on Ventricular Hypertrophy in Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials",
    "cover-date": "2022-04-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Cardiology and Cardiovascular Medicine",
            "@code": "2705",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Angiotensin II receptor blocker",
        "Hypertrophic cardiomyopathy",
        "Left ventricular ejection fraction",
        "Left ventricular mass"
    ],
    "authors": [
        "Ye Liu",
        "Kanako Teramoto",
        "Vicki K. Wing",
        "Thanan Supasiri",
        "Kanhua Yin"
    ],
    "citedby-count": 3,
    "ref-count": 40,
    "ref-list": [
        "The molecular genetic basis for hypertrophic cardiomyopathy",
        "Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy",
        "Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives",
        "Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy",
        "Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-\u03b2",
        "Impact of renin-angiotensin system polymorphisms on development of systolic dysfunction in hypertrophic cardiomyopathy. Evidence from a study of genotyped patients",
        "A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker",
        "Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy",
        "Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial",
        "Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial",
        "2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)",
        "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement",
        "Assessing the quality of reports of randomized clinical trials: is blinding necessary?",
        "Estimation of human myocardial mass with MR imaging",
        "Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy",
        "The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study",
        "Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension",
        "Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study",
        "Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension",
        "Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies",
        "Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)",
        "A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension",
        "Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies",
        "Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial",
        "Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol",
        "Genetics of hypertrophic cardiomyopathy: advances and pitfalls in molecular diagnosis and therapy",
        "Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy",
        "Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene",
        "Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy",
        "The significance of interstitial fibrosis on left ventricular function in hypertensive versus hypertrophic cardiomyopathy",
        "Left ventricular mass in hypertrophic cardiomyopathy assessed by 2D-echocardiography: validation with magnetic resonance imaging",
        "Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings",
        "Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology",
        "Echocardiographic comparison between left ventricular non-compaction and hypertrophic cardiomyopathy",
        "Echocardiographic diagnosis of the different phenotypes of hypertrophic cardiomyopathy",
        "The design of the valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy (VANISH) trial",
        "Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial",
        "Characterization of the cardiac myosin inhibitor CK-3773274: a potential therapeutic approach for hypertrophic cardiomyopathy",
        "Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy"
    ],
    "affiliation": [
        {
            "affiliation-city": "Birmingham",
            "@id": "60033096",
            "affilname": "University of Alabama at Birmingham School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033096",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60032499",
            "affilname": "Harvard T.H. Chan School of Public Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032499",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Boston",
            "@id": "60029929",
            "affilname": "Massachusetts General Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029929",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Kawasaki",
            "@id": "60012275",
            "affilname": "St. Marianna University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012275",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Harvard University Countway Library of Medicine",
        "Harvard T.H. Chan School of Public Health"
    ]
}